ACA
AYTU icon

Affinity Capital Advisors’s AYTU BioPharma AYTU Stock Holding History

Affinity Capital Advisors’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-571
Closed -$2.16K – 126
2022
Q4 		$2.16K Hold
571
– – ﹤0.01% 110
2022
Q3 		$2K Buy
+571
New +$4.33K ﹤0.01% 107

Other funds holding AYTU

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Affinity Capital Advisors's AYTU Position: Q1 2023 in Review

Affinity Capital Advisors sold out of AYTU BioPharma (AYTU) in Q1 2023, closing a stake of 571 shares — an estimated $2.16K sold.

Affinity Capital Advisors first reported a position in AYTU in Q3 2022 and held it in 2 quarters. The position peaked at $2.16K in Q4 2022. 21 funds tracked by Wall St. Rank hold AYTU as of Q1 2023.

  • Affinity Capital Advisors reported no remaining AYTU BioPharma position as of Q1 2023 after selling out during the quarter.
  • Affinity Capital Advisors sold 571 AYTU BioPharma shares in Q1 2023, an estimated $2.16K.
  • Affinity Capital Advisors first reported a position in AYTU BioPharma in Q3 2022 and held it in 2 quarters.
  • Affinity Capital Advisors's AYTU BioPharma position peaked at $2.16K in Q4 2022.
  • 21 funds tracked by Wall St. Rank held AYTU BioPharma as of Q1 2023.

Based on Affinity Capital Advisors's 13F filing for Q1 2023, filed 11 Apr 2023.